<DOC>
	<DOC>NCT00862992</DOC>
	<brief_summary>The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets will be administered to patients starting at an initial dose, followed by up-titration to a fixed dose (low, medium or high) for 14 days.</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients meeting DSMIVTR criteria for schizophrenia PANSS total score &lt;= 120 during the observation period Patients who have been treated with oral antipsychotics within 4 weeks before informed consent Patients whose consent is obtained from themselves in written form Patients who have defined as any mental disorder other than "Schizophrenia" based on the criteria of DSMIVTR History of drug or alcohol abuse Concurrent Parkinson's disease History of, or concurrent spastic disorders like epilepsy, cerebrovascular disease, anuresis or adynamic(= paralytic) ileus, malignant syndrome, diabetes, hepatic disorder Patients who exhibit abnormalities on Physical Examination, have abnormal vital signs, ECG, or clinical laboratory values Current cataract during the observation period History of shock or anaphylactoid symptoms to drugs</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>antipsychotics</keyword>
	<keyword>dopamine D3/D2 antagonist</keyword>
</DOC>